DEC 27, 2020 2:15 AM PST

Attacking Mitochondria in Tumors

WRITTEN BY: Nouran Amin

Researchers found that attacking a cell’s mitochondria can starve cancer cells. The study involves a possible therapeutic for anti-tumor activity.

"We managed to establish a potential cancer drug that targets mitochondrial function without severe side effects and without harming healthy cells," explains Nina Bonekamp, one of the lead authors of the study.

The therapeutic works by preventing the genetic material of the mitochondria, or mitochondrial DNA (mtDNA), from being decoded. The mitochondria serve as the cells “powerhouse” providing necessary energy for basic tissue and organ function.

Learn more about mitochondria activity:

"Previous findings of our group have shown that rapidly proliferating cells, such as embryonic cells, are very sensitive to inhibition of mtDNA expression, whereas differentiated tissues such as skeletal muscle can tolerate this condition for a surprisingly long time. We reasoned that POLRMT as a key regulator of mtDNA expression might provide a promising target," says Nils-Göran Larsson, head of the research team.

Specifically, the compound inhibits mitochondrial RNA polymerase activity.

"Our data suggest that we basically starve cancer cells into dying without large toxic side effects, at least for a certain amount of time. This provides us with a potential window of opportunity for treatment of cancer," says Nina Bonekamp. "Another advantage of our inhibitor is that we exactly know where it binds to POLRMT and what it does to the protein. This is in contrast to some other drugs that are even in clinical use."

"Given the central role of mitochondrial metabolism within the cell, I am sure that our inhibitor of mitochondrial gene expression can be used as a tool in a variety of different areas," explains Bonekamp. "Of course, it is intriguing to further pursue its potential as an anti-cancer drug, but also as a model compound to further understand the cellular effects of mitochondrial dysfunction and mitochondrial diseases."

Source: Science Daily

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
FEB 11, 2021
Drug Discovery & Development
Antibiotic-Use During Pregnancy
FEB 11, 2021
Antibiotic-Use During Pregnancy
A study published in the Archives of Disease in Childhood, shows that fetal exposure to antibiotics in mid to late pregn ...
MAR 18, 2021
Drug Discovery & Development
New Cancer Immunotherapy Targets Genetic Alteration in All Cancers
MAR 18, 2021
New Cancer Immunotherapy Targets Genetic Alteration in All Cancers
Researchers have developed a prototype for a new kind of cancer immunotherapy. The therapy uses engineered T-cells to ta ...
APR 02, 2021
Technology
Protein Modeling of SARS-CoV-2 Provides Targets for Vaccine Development
APR 02, 2021
Protein Modeling of SARS-CoV-2 Provides Targets for Vaccine Development
Recent protein modeling of the SARS-CoV-2 spike protein reveals novel areas for vaccine development. The novel SARS-CoV- ...
APR 17, 2021
Drug Discovery & Development
Facebook AI May Speed up Cancer Drug Discovery
APR 17, 2021
Facebook AI May Speed up Cancer Drug Discovery
Facebook has claimed that its new artificial intelligence, known as 'Compositional Perturbation Autoencoder' (CP ...
APR 22, 2021
Drug Discovery & Development
mRNA Covid Vaccines May Protect Against New Strains and Common Cold
APR 22, 2021
mRNA Covid Vaccines May Protect Against New Strains and Common Cold
Researchers from Johns Hopkins have found that the mRNA Covid vaccines developed by Pfizer and Moderna not only work wit ...
MAY 06, 2021
Cannabis Sciences
New CBD Analog Outperforms Regular CBD for Pain Relief
MAY 06, 2021
New CBD Analog Outperforms Regular CBD for Pain Relief
Researchers from Temple University Health System have found that a novel cannabidiol (CBD) analog can reverse pain sensi ...
Loading Comments...